ClinicalTrials.Veeva

Menu

Injection Intervals in Real-world Neovascular Age-related Macular Degeneration (nAMD) Patients Switching to Brolucizumab With at Least 12 Months of Follow-up

Novartis logo

Novartis

Status

Completed

Conditions

Neovascular Age-related Macular Degeneration

Study type

Observational

Funder types

Industry

Identifiers

NCT06178770
CRTH258A2018

Details and patient eligibility

About

This retrospective study included nAMD patients whose eyes were grouped into the following cohorts, with the overall cohort receiving ≥ 1 brolucizumab injection; the 12-month and 18-month brolucizumab (BRO) cohorts, which consisted of nAMD patient eyes who switched from a previous anti-vascular endothelial growth factor (VEGF) and had ≥3 brolucizumab injections with no other anti-VEGF in the first 12 months (360 days) and 18 months (540 days) of follow-up respectively; and the 12-month and 18-month alternating (ALT) cohorts, which consisted of nAMD patient eyes who switched from a previous anti-VEGF to brolucizumab and had ≥2 brolucizumab injections and ≥1 injection of another anti-VEGF in the first 12 months and 18 months of follow-up, respectively.

Enrollment

414 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Patients with a diagnosis of nAMD.
  • Patients were on a previous anti-VEGF therapy and then switched to brolucizumab.
  • Patients remained on brolucizumab for at least 12 months.
  • Patients had exactly 360 days or more of follow-up after first brolucizumab injection.
  • For BRO cohort only: Patients received at least three injections of brolucizumab during study period.
  • For ALT cohort only: Patients received at least two injections of brolucizumab and one injection of another anti-VEGF during the study period.

Exclusion criteria

  • For BRO cohort only: Patients who received any other anti-VEGF therapy during the 12-month follow-up period.
  • Eyes missing bilaterality information in their nAMD diagnosis.
  • Eyes missing bilaterality information in their brolucizumab injections.

Trial design

414 participants in 5 patient groups

Overall cohort
12-month BRO cohort
18-month BRO cohort
12-month ALT cohort
18-month ALT cohort

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems